Statistics for The efficacy and drug survival of the biosimilar infliximab (ct-p13) compared to the original reference infliximab in inflammatory rheumatic diseases; Results from the turkbio registry
Total visits
| views | |
|---|---|
| The efficacy and drug survival of the biosimilar infliximab (ct-p13) compared to the original reference infliximab in inflammatory rheumatic diseases; Results from the turkbio registry | 2 |
Total visits per month
| views | |
|---|---|
| May 2024 | 0 |
| June 2024 | 0 |
| July 2024 | 0 |
| August 2024 | 0 |
| September 2024 | 0 |
| October 2024 | 0 |
| November 2024 | 0 |
Top country views
| views | |
|---|---|
| India | 1 |
Top city views
| views | |
|---|---|
| Hyderabad | 1 |